Rotigotine Transdermal Patches Market Size, Share, By Type (Standard Patch, Extended-Release Patch, Combination Patch, Innovative Delivery Systems, and Others), Patch Technology ( Matrix Patch, Reservoir Patch, Micro needle-assisted Patch, Polymeric/Adhesive Technology, Extended-release/Controlled-release Technology, and Others), Strength [(Low dose (2 mg/24h, 4 mg/24h), Medium dose (6 mg/24h, 8 mg/24h), High dose(10 mg/24h, 12 mg/24h), and Others)], Application (Parkinson’s Disease, Restless Legs Syndrome (RLS), Neuropathic Pain, Cognitive Disorders, Sleep Disorders, and Others), End Users (Hospitals & Neurology Clinics, Rehabilitation Centers, Specialty Care Centers, Homecare/ Self-Administration, Clinical Research Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

Report Code: PMI264619 | Publish Date: December 2023 | No. of Pages: 182

Global Rotigotine Transdermal Patches Market Companies

In order to improve their market reach and confidence, companies should promote transdermal drug delivery technologies, enhance patient comfort, and increase clinical evidence through multinational studies. Market access in new regions can be enhanced through strategic alliances, patient education, and optimized pricing and reimbursement strategies. Key player for the rotigotine transdermal patches market are UCB S.A. and Luye Pharma AG.

List of Key Players in the Market:

  • UCB S.A.
  • Luye Pharma AG
  • BioNxt Solutions
  • Shilpa Medicare
  • Aderis Pharmaceuticals
  • Otsuka Pharmaceutical Co., Ltd.
  • Kyowa Kirin Co., Ltd.
  • LTS Lohmann Therapie-Systeme AG

Recent News:

  • Luye Pharma Group has commercialized its RotigotineLuye transdermal patch in 2025. The U.K. and Germany, used for Parkinson disease and restless legs syndrome. UnsuchasNeupro, it has a smaller diameter and lower payload, reducing allergic reactions and demonstrating Luye Pharma's interest in central nervous system therapeutics.
  • A study suggests a patch of microarray preloaded with nanosuspension of rotigotine as a potential replacement for conventional patches in 2024. This technology enhances delivery effectiveness and produces therapeutic levels over sustained periods, potentially improving outcomes and patient adherence in Parkinson disease.